Voyager Therapeutics, Inc. Common Stock
$3.05
-$0.04 (-1.29%)
$2.97Day Range$3.11
Key Statistics
Market Cap
$190.40M
Shares Outstanding
61.6M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Nov 11, 2015
Round Lot
100
Locale
US
Trading Data
Day Open
$3.11
Day High
$3.11
Day Low
$2.97
Volume
633.4K
VWAP
$3.03
Prev Close
$3.09
Transactions
--
Acc. Volume
--
About Voyager Therapeutics, Inc. Common Stock
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)SIC 2836141 employees75 HAYDEN AVENUE, LEXINGTON, MA, 02421857-259-5340IPO Nov 11, 2015US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001640266
- Composite FIGI
- BBG005ZSY233
- Share Class FIGI
- BBG005ZSY242
- Ticker Root
- VYGR
- SIC Code
- 2836
About Voyager Therapeutics, Inc. Common Stock (VYGR) Stock
Voyager Therapeutics, Inc. Common Stock (VYGR) closed the 2026-09-16 session at $3.05, down 1.29% versus the previous close (-0.04). The stock opened at $3.11 and traded between $2.97 and $3.11 during that session. Session trading volume was 633K shares. The volume-weighted average price (VWAP) is $3.03.
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.
Voyager Therapeutics, Inc. Common Stock has a market capitalization of $190.4 million. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. VYGR is listed on the XNAS exchange. The company employs approximately 141 people. Voyager Therapeutics, Inc. Common Stock is headquartered in LEXINGTON, MA. The recorded listing date is 2015-11-11.
On this page you can find market VYGR stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.